A billion healthy years.
One breakthrough at a time.
Pμre BioHealth is a biotechnology company built on a singular, world-first scientific breakthrough — the only patented, published technology demonstrated to reduce microplastic and glyphosate burden in living biological systems.
In an era when microplastics and chemical contaminants have infiltrated every corner of our environment — our food, our water, our air, and our bodies — we built the science to fight back. Our patented Plastic Adsorptive Compound (PAC) technology binds, removes, and helps the body restore itself from the invisible toxic load accumulating in human tissue, companion animals, and the agricultural systems that feed the world.
Our work spans three pillars: Pμre Health for people, Pμre Pet for companion animals, and Pμre BioFarm for the livestock and agricultural systems that sustain civilization.
Our mission is both ambitious and simple: to contribute one billion healthy years to the lives of people across the planet. Every product, every partnership, every published study moves us closer to that number — because we believe that longevity begins with protecting the biological systems that make life possible.
Meet the Team
CEO, Co-Founder & Board of Directors
Three decades building and scaling biotech and consumer health companies worldwide. Former Vice President at John Paul Mitchell Systems, a global brand portfolio spanning 100+ countries. Now creating an entirely new category at the intersection of science, health, and environmental defense — from human wellness to companion animals to agriculture.
Dr. J. Phillip Kennedy, Ph.D.
Founder, Chief Science Officer & Board of Directors
25+ years in pharmaceutical research, medicinal chemistry, and novel market development. Proven track record in patent creation and IP portfolio building. Expert at translating scientific discoveries into commercial opportunities.
PATENTS
Waugh, J. M.; Kennedy, J.P.; (2014), Minocycline Derivatives for Treatment of Bacterial Infections. PCT Int. Appl., Patent No. WO 2014151347 A1 20140925
Lindsley, C.W.; Conn, J.P.; Kennedy, J.P.; Brogan, J.T.; (2009), Synthesis of Unnatural Dispyrin Analogues and Uses Thereof. Patent No. WO 2009152071.
Waugh, J. M.; Kennedy, J.P.; (2016), Minocycline Derivatives US20160030452A1
Kennedy, J.P. Skin lightening Anti-aging and Skin Tone Lightening Compositions and Methods for Same US 34845188.
-Private Patents- Under NDA -Topics only- Internal Review Only-
Kennedy, J.P. Compositions for Treating Dermatological Diseases
Kennedy, J.P. Oral Bioenhancers
Kennedy, J.P. Weight loss Technology
Kennedy, J.P. Cancer Therapeutics
Kennedy, J.P. Modified Cancer Therapeutics
Kennedy, J.P. Diabetes Technology
Kennedy, J.P. Bioenhancer Refinement
PEER REVIEWED PUBLICATIONS
37. Abbott, J.R.; Hodges, T.R.; Daniels, R.N.; Patel, P.A.; Kennedy J P.; et al. (2018), Discovery of Aminopiperidine Indoles That Activate the Guanine Nucleotide Exchange Factor SOS1 and Modulate RAS Signaling. J. Med. Chem. 61 (14), pp 6002–6017.
36. Waterson, A. G.; Kennedy, J. P.; Patrone, J. D.; et al. (2015), Diphenylpyrazoles as Replication Protein A Inhibitors. ACS Med. Chem. Lett. 6(2), 140-145.
35. Lee, Jane; Kennedy, J. P.; Waugh, Jacob M.; (2015), Experience with CPP-Based Self Assembling Peptide Systems For Topical Delivery of Botulinum Toxin. Methods in molecular biology (Clifton, N.J.) (2015), 1324, 397-415.
34. Burns M. C; Sun Q.; Daniels R. N.; et al. (2014) Approach for targeting Ras with small molecules that activate SOS-mediated nucleotide exchange. PNAS 111(9), 3401-6.
33. Feldkamp, M. D.; Frank, A. O.; Kennedy, J. P.; et al. (2013) Biochemistry. 52(37), 6515-6524.
32. Feldkamp M. D; Frank A. O; Kennedy J. P.; et al. (2013), Surface reengineering of RPA70N enables cocrystallization with an inhibitor of the replication protein A interaction motif of ATR interacting protein. Biochemistry. 52(37), 6515-24.
31. Frank, A. O.; Feldkamp, M. D.; Kennedy, J. P.; et al. (2013), Discovery of a Potent Inhibitor of Replication Protein A Protein-Protein Interactions Using a Fragment-Linking Approach. J. Med. Chem. 56(22), 9242-9250.
30. Patrone, J. D.; Kennedy, J. P.; et al. (2013), Fragment-based Discovery of Protein-Protein Interaction Inhibitors of Replication Protein A. ACS Med. Chem. Lett. 4(7):601-605.
29. Lindsley, C. W.; Weaver, D.; Bridges, T. M.; Kennedy, J. P. (2012) Lead Optimization in Drug Discovery. Chemical Biology, 65-81.
28. Speed, N. K.; Saunders, C.; Davis, A.R.; et al. (2011), Impaired Striatal Akt Signaling Disrupts Dopamine Homeostasis and Increases Feeding. PLoS One 6(9):e25169.
27. Speed, N. K.; Matthies, H. J. G.; Kennedy, J. P.; et al. (2010), Akt-dependent and Isoform-specific Regulation of Dopamine Transporter Cell Surface Expression. ACS Chemical Neuroscience 1(7):476-481.
26. Kennedy, J. P.; Lindsley, C. W.; (2010), Progress Towards the Synthesis of Piperazimycin A: Synthesis of the Non-proteoenic Amino Acids and Elaboration into Dipeptides. Tet. Lett. 51(18):2493-2496.
25. Siuta, M. A.; Robertson, S. D.; et al. (2010), Dysregulation of the Norepinephrine Transporter Sustains Cortical Hypodopaminergia and Schizophrenia-like Behaviors in Neuronal Rictor Null Mice. PLoS Biology, 8(6):e1000393.
24. Lebois, E. P.; Bridges, T. M.; Lewis, L. M.; et al. (2010), Discovery and Characterization of Novel Subtype-Selective Allosteric Agonists for the Investigation of M1 Receptor Function in the Central Nervous System. ACS Chemical Neuroscience, 1(2):104-121.
23. Bridges, T. M.; Kennedy, J. P.; Hopkins, C. R.; et al. (2010), Heterobiaryl and Heterobiaryl Ether Derived M5 Positive Allosteric Modulators. Bioorg. Med. Chem. Lett. 20(19):5617-5622.
22. Robertson, S.D.; Matthies, H. J. G.; et al. (2010), Insulin Reveals Akt Signaling as a Novel Regulator of Norepinephrine Transporter Trafficking and Norepinephrine Homeostasis. J. Neurosci. 30(34):11305-11316.
21. Bridges, T.M.; Kennedy, J.P.; et al. (2010), Chemical Lead Optimization of a pan Gq mAChR M1, M3, M5 Positive Allosteric Modulator (PAM) Lead. Part I: Development of the First Highly Selective M5 PAM. Bioorg. Med. Chem. Lett. 20(2):558-562.
20. Kennedy, J.P.; Breininger, M. L.; Lindsley, C. W.; (2009), Total Synthesis of Eudistomans Y1-Y6. Tet. Lett. 50(50):7067-7069.
19. Kennedy, J.P.; Conn, P.J.; Lindsley, C.W.; (2009), A Novel Class of H3 Antagonists Derived from the Natural Product Guided Synthesis of Unnatural Analogs of the Marine Bromopyrrole Alkaloid Dispyrin. Bioorg. Med. Chem. Lett. 19(12):3204-08.
18. Shirley, J.K.; Brady, A.E.; Jones, P.J.; et al. (2009), A Selective Allosteric Potentiator of the M1 Muscarinic Acetylcholine Receptor Increases Activity of Medial Prefrontal Cortical Neurons and Restores Impairments in Reversal Learning. J. Neurosci. 23(45):14271-14286.
17. Weaver, C.D.; Sheffler, D.J.; Lewis, L.M.; et al. (2009), Discovery and Development of a Potent and Highly Selective Small Molecule Muscarinic Acetylcholine Receptor Subtype I (mAChR 1 or M1) Antagonist in vitro and in vivo Probe. Curr. Top. Med. Chem. 9(13):1217-1226.
16. Lindsley, C.W.; Weaver, C.D.; Bridges, T.M.; Kennedy, J.P.; (2009) Lead Optimization in Drug Discovery. Wiley Encyclopedia of Chemical Biology.
15. Miller, T.W.; et al. (2009) Loss of Phosphatase and Tensin Homologue Deleted on Chromosome 10 Engages ErbB3 and Insulin-Like Growth Factor-I Receptor Signaling to Promote Antiestrogen Resistance in Breast Cancer. Can. Res. 69(10):4192-01.
14. Kennedy, J.P.; Bridges, T.M.; et al. (2009), Synthesis and Structure-Activity Relationships of Allosteric Potentiators of the M4 Muscarinic Acetylcholine Receptor. ChemMedChem. 4(10):1600-1607.
13. Kennedy, J.P.; Williams, L.; Bridges, T.M.; et al. (2008), Application of Combinatorial Chemistry Science on Modern Drug Discovery. J. Comb. Chem. 10(3):345-54.
12. Brady, A.E.; Jones, C.K.; Bridges, T.M.; Kennedy, J.P.; et al. (2008), Centrally Active Allosteric Potentiators of the M4 Muscarinic Acetylcholine Receptor Reverse Amphetamine Induced Hyperlocomotion Activity in Rats. J. Pharacol. Exp. Ther. 327(3):941-53.
11. Jones, C.K.; Brady, A.E.; Davis, A.A.; et al. (2008), Novel Selective Allosteric Activator of the M1 Muscarinic Acetylcholine Receptor Regulates Amyloid Processing and Produces Antipsychotic-like Activity in Rats. J. Neurosci. 28(41):10422-33.
10. Kennedy, J.P.; Brogan, J.T.; Lindsley, C.W.; (2008), Progress Toward the Synthesis of Piperazimycin A: Exploration of the Synthesis of γ-hydroxy and γ-chloropiperazic acids. Tet. Lett. 49(26):4116-18.
9. Bridges, T.M.; Brady, A.E.; Kennedy, J.P.; et al. (2008), Synthesis and SAR of Analogues of the M1 Allosteric Agonist. Part I. Bioorg. Med. Chem. Lett. 18(20):5439-42.
8. Lewis, L.M.; Sheffler, D.; Williams, R.; et al. (2008), Synthesis and SAR of Selective Muscarinic Acetylcholine Receptor Subtype 1 (M1 mAChR) Antagonists. Bioorg. Med. Chem. Lett. 18(3);885-90.
7. Kennedy, J.P.; Brogan, J.T.; Lindsley, C.W.; (2008), Total Synthesis and Biological Evaluation of the Marine Bromopyrrole Alkaloid Dispyrin: Elucidation of Discrete Molecular Targets with Therapeutic Potential. J. Nat. Prod. 71(10):1783-86.
6. Kennedy, J.P.; Lindsley, C.W.; (2007), Molecule of the Month. Curr. Top. Med. Chem. 7(12):1248.
5. Silvaggi, N.R.; Boldt, G.E.; Hixon, M.S.; Kennedy, J.P.; et al. (2007), Structures of Clostridium Botulinum Neurotoxin Serotype A Light Chain Complexed with Small-Molecule Inhibitors Highlight Active-Site Flexibility. Chem. Bio. 14(5):533-42.
4. Xu, Y.; Lu, H.; Kennedy, J.P.; et al. (2006), Evaluation of "Credit Card" Libraries for Inhibition of HIV-1 gp41 Fusogenic Core Formation. J. Comb. Chem. 8(4):531-39.
3. Boldt, G.E.; Kennedy, J.P.; Janda, J.P.; (2006), Identification of a Potent Botulinum Neurotoxin A Protease Inhibitor Using in Situ Lead Identification Chemistry. Org. Lett. 8(8):1729-32.
2. McAllister, L.A.; Hixon, M.S.; Kennedy, J.P.; et al. (2006), Superactivation of the Botulinum Neurotoxin Serotype A Light Chain Metalloprotease: A New Wrinkle in Botulinum Neurotoxin. J. Am. Chem. Soc. 128(13):4176-77.
1. Boldt, G.E.; Kennedy, J.P.; Hixon, M.S.; et al. (2006), Synthesis, Characterization and Development of a High-Throughput Methodology for the Discovery of Botulinum Neurotoxin A Inhibitors. J. Comb. Chem. 8(4), 513-21.
Dr. Janet Zand, O.M.D., Lic. Ac., Diplomat OM, CCN
Co-Founder, Chief Innovation Officer & Board of Directors
30+ years building mission-driven health organizations. Founder of Zand Herbal Formulas (1978). Co-Founder of Humann (2009). Former Chair of NCCAOM. Author of Smart Medicine for a Healthier Child.
Dr. Debra Kimless, M.D.
Chief Medical Officer
Board-certified Anesthesiologist with Pain Medicine and Lifestyle Medicine certifications. Rutgers MD, magna cum laude. Pioneer in medical cannabis research since 2013. Lead author on cannabinoid patent. Author of Plant Struck.
Dr. Benjamin Katz, Ph.D.
Scientific Advisor — Mass Spectrometry & Microplastics
Proteomics Specialist at UC Irvine with 17+ years expertise and 1,200+ citations. B.S.E. Biomedical Engineering, Georgia Tech. Expert in HPLC, ESI, and MALDI-TOF for microplastics detection in biological samples.
Dr. Curtis Wadsworth, J.D., Ph.D.
Legal & IP Advisor
Is the founder of Nerd Lawyer Entrepreneur Services with a deep expertise in biotech IP, nutraceuticals, and pharmaceuticals. Ph.D. Molecular Biology (Pittsburgh), J.D. (Duquesne). Founded DorothyAI.
Dale Hayes
President of Pure BioFarm
Dale Hayes was born and raised in central Florida where he developed his love of nature and wildlife conservation. He is a graduate of the University of Florida where he earned a Bachelor Degree in both Animal Science and Food & Resource Economics. Dale has had successful careers in production agriculture and agricultural allied industries. As a result, he brings a variety of skillsets developed from operating large farm production systems to managing various business segments for global manufacturing companies. Dale is married to his wife of 34 years, has three children, one son-in-law, is an avid outdoorsman and is active in his local church, various conservation groups & faith-based ministries.
Pablo Talledo
Product & Operations Manager
Industrial Engineer and UCLA Anderson MBA with 8+ years of experience in business development, strategy, and consumer brand growth. Entrepreneur with hands-on experience building CPG brands, launching products, developing partnerships, and scaling go-to-market efforts.
Kathleen Hutchens
Environmental Impact Strategist
Kathleen graduated from UC Santa Barbara magna cum laude with dual honors in Environmental Studies and Geography, earning university, dean's, and departmental recognition. She co-leads the design of the company's website and product labels, and serves as the architect of its environmental ethos — ensuring sustainability values are clearly articulated across branding, messaging, and strategy. Kathleen develops and delivers strategic presentations for high-level stakeholder engagements, translating complex environmental insights into compelling, visual narratives. She also leads the company's environmental presence, shaping its public identity at the intersection of wellness and sustainability.
Notable Shareholders
John Paul DeJoria
Strategic Advisor to the Board and Shareholder
Billionaire entrepreneur and philanthropist. Co-founder of John Paul Mitchell Systems and Patron Spirits (sold to Bacardi for $5.1B). Serial investor in disruptive health and wellness ventures.
Get In Touch
Contact Us
- Choosing a selection results in a full page refresh.
- Opens in a new window.